Daliya Pencheva
Daliya is a rheumatology resident at the University Hospital “St. Ivan Rilski”, Sofia, Bulgaria. Her major interests are systemic lupus erythematosus, quality of life, patient-reported outcome measures, treat-to-target therapy. Daliyais a member of the Newsletter Sub-Committee.
| Type, n° | Date, time | Session | Author | Title |
|---|---|---|---|---|
| Oral 0136 | Thursday, 01.06.2022 10:35 – 10:45 | The future perspectives in the treatment of SLE & Sjören’s | Jayne, D (USA) | METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS |
| The study conducted metabolomic serum profiling to identify novel biomarkers of treatment response and provide insights into the mechanism of action of anifrolumab in lupus nephritis (LN). | ||||
| Oral 0141 | Thursday, 01.06.2023 11:15 – 11:25 | The future perspectives in the treatment of SLE & Sjören’s | Schett, G (Germany) | LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS – DATA FROM THE FIRST SEVEN PATIENTS |
| The study suggests that CD19 CAR T-cell therapy can abrogate disease and delete autoimmunity in patients with severe systemic lupus erythematosus (SLE), as the longest disease-free observation period is now 22 months.. | ||||
| Poster 0112 | Thursday, 01.06.2023 12:05 | A novel journey into SLE, Sjogren and APS | Kahlenberg, JM (USA) | DEUCRAVACITINIB REDUCES INTERFERONS, B-CELL PATHWAYS, AND SEROLOGICAL BIOMARKERS OF SYSTEMIC LUPUS DISEASE ACTIVITY: PHARMACODYNAMIC ANALYSIS FROM THE PHASE 2 PAISLEY STUDY |
| In the phase 2 PAISLEY SLE trial Deucravacitinib suppressed IFN production, IRG expression, IFN-inducible proteins, B-cell pathway markers, and serological biomarkers, consistent with clinical symptom improvements in SLE patients. | ||||
| Oral 0226 | Friday, 02.06.2023 10:35 – 10:45 | Updates on management and outcomes in SLE and Sjogren syndrome | Morand, EF (Australia) | ATTAINMENT OF LUPUS LOW DISEASE ACTIVITY STATE EXCLUSIVE OF REMISSION IS PROTECTIVE AGAINST ADVERSE OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS |
| Data from a 13-country SLE cohort showed attainment of LLDAS is an independent predictor of improved outcomes in SLE. | ||||
| Oral 0230 | Friday, 02.06.2023 11:15 – 11:25 | Updates on management and outcomes in SLE and Sjogren syndrome | Kawka, L (France) | USING AN INNOVATIVE DIGITAL TOOL FOR THE ASSESSMENT AND PERSONALIZED RECOMMENDATIONS TO COPE WITH FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS: THE LEAF STUDY |
| The «Lupus Expert System for Assessment of Fatigue» LEAF is an online digital tool for fatigue management in SLE. | ||||
| Poster 0172 | Friday, 02.06.2023 12:45 | SLE, Sjögren’s and APS – clinical aspects (other than treatment) | Evangelatos, G (Greece) | ARTERIAL STIFFNESS IN ANTIPHOSPHOLIPID SYNDROME: COMPARISON WITH DIABETES MELLITUS AND HEALTHY CONTROLS |
| The study suggests that arterial stiffness (ArS) evaluation may help to improve cardiovascular risk stratification in APS patient. | ||||